An Open-label Study in Healthy Adults to Evaluate the Relative Bioequivalence of a Single-dose Administration of Sonelokimab Either by a Prefilled Syringe or an Autoinjector

NCT06994936 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

120

Enrollment

INDUSTRY

Sponsor class

Conditions

Relative Bioequivalence

Interventions

DRUG: Sonelokimab
DRUG: Sonelokimab

Sponsor

MoonLake Immunotherapeutics AG